Interspecies in vitro metabolism of the phosphodiesterase‐4 (PDE4) inhibitor L‐454,560
- 16 May 2006
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 41 (6) , 771-780
Abstract
L‐454,560 is a potent phospodiesterase 4 (PDE4) inhibitor which was identified as a development candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of the discovery of this compound, interspecies in vitro metabolism data was generated using liver microsomes and hepatocytes in order to understand the metabolic fate of the compound. In microsomes, metabolism of the 3‐methyl‐1,2,4‐oxadiazole ring was the predominant pathway observed, including ring cleavage. In rat hepatocytes, hydroxylation of the methyl group on the oxadiazole ring and double‐bond isomerization were the most abundant metabolites observed. No major species differences were found in terms of microsomal metabolite profiles. The use of LC with UV and MS detection is highlighted, as well as information from tandem mass spectrometry and NMR. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure–activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitorBioorganic & Medicinal Chemistry Letters, 2005
- USE OF A BENZYLOXY-SUBSTITUTED LACTONE CYCLOOXYGENASE-2 INHIBITOR AS A SELECTIVE FLUORESCENT PROBE FOR CYP3A ACTIVITY IN PRIMARY CULTURED RAT AND HUMAN HEPATOCYTESDrug Metabolism and Disposition, 2004
- Simultaneous determination of MK‐0767 and seven metabolites in rat urine using liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2004
- Preferential Inhibition of T Helper 1, but Not T Helper 2, Cytokines in Vitro by L-826,141 [4-{2-(3,4-Bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 InhibitorThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent bindingBioorganic & Medicinal Chemistry Letters, 2002
- Tandem mass spectrum of a farnesyl transferase inhibitor— gas‐phase rearrangements involving imidazoleJournal of Mass Spectrometry, 2001
- PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea‐pigsClinical & Experimental Allergy, 1998
- Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthmaCanadian Journal of Physiology and Pharmacology, 1998
- The Multienzyme PDE4 Cyclic Adenosine Monophosphate–Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions1998
- The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheepEuropean Journal of Pharmacology, 1992